Industry – AML-ALL US Focus Meeting 2023

AML-ALL US Focus Meeting 2023

Course Information

Course Instructor

Author

AML-ALL US Focus Meeting 2023

$1,000.00

Registration fee

Complimentary coupon code for supporters can be added at checkout.

Introduction

Ryan Fitzpatrick

Session I

The genetic landscape and molecular diagnostics in AML – Joe Khoury, University of Nebraska Medical Center

Optimizing frontline therapy for FLT3 mutated AML patients eligible for Intensive Chemotherapy – Harry Erba, Duke Blood Cancer Center, Durham

Genomic strategies to guide the choice of intensive treatment strategies in non-FLT3m AML – Amir Fathi, Massachusetts General Hospital, Boston

Diagnostic and Molecular Work-up of Newly Diagnosed AML – The Pathologists’ Perspective – Sanam Loghavi, MD Anderson Cancer Center Houston, Texas

Panel Discussion

Session II

Updates on the management and mechanisns of resistance in R/R FT3 mutated AML – Alexander E. Perl, Hospital of University of Pennsylvania, Philadelphia PA

How do I assess for MRD in clinical practice and how do I use MRD to guide post remission therapy – Farhad Ravandi, MD Anderson Cancer Center Houston, Texas

How do I use IDH inhibitors in the frontline and R/R Setting: Single agent versus combinations – Courtney DiNardo, MD Anderson Cancer Center Houston, Texas

Current status and future directions with menin inhibitors in AML – Eytan Stein, Memorial Sloan Kettering Cancer Center, New York

Panel Discussion

Session III

The case for upfront triplets – Naval Daver, MD Anderson Cancer Center, Houston, Texas

The case for sequential triplets – Jessica Altman, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

Panel Discussion

Developing immune and cellular therapies in AML – Yasmin Abaza, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

How do I Manage AML Patients Receiving HMA/venetoclax based therapies; A focus on practical approaches – Brian Jonas, UC Davis Health, Sacramento, CA

Panel Discussion

Session IV

Mechanisms of resistance and novel combinations with venetoclax based therapies in AML – Marina Konopleva, MD Anderson Cancer Center Houston, Texas

Optimizing maintenance therapy in AML post-consolidation and post-transplant – Tapan Kadia, MD Anderson Cancer Center, Houston, Texas

Immune based approaches in AML/MDS – Hetty Carraway, Cleveland Clinic, Ohio

Optimizing SCT approaches including conditioning and maintenance in AML – Andrew Artz, City of Hope, Chicago, Illinois

Panel Discussion

Astellas Sponsored Expert Discussion

Session V

Incorperating targeted therapies: Menin, FLT3, IDH and others in pediatric populations – Branko Cuglievan, MD Anderson Cancer Center, Houston, Texas

The genetic landscape and molecular diagnostics in ALL – Charles Mullighan, St. Jude Children’s Research Hospital, Memphis, Tennessee

Walking away from chemotherapy – Elias Jabbour, MD Anderson Cancer Center, Houston, Texas

When to transplant in ALL – Mark Litzow, Mayo Clinic Comprehensive Cancer Center

Panel Discussion

Session VI

Debate 1: Integration of immunotherapy into frontline therapy – Inotuzumab Ryan Cassaday, Fred Hutchinson Cancer Center, Seattle, Washington

Debate 1: Integration of immunotherapy into frontline therapy – Blinatumomab Anjali Advani, Cleveland Clinic, Ohio

Debate 1: Integration of immunotherapy into frontline therapy – Discussion

Debate 1: Integration of immunotherapy into frontline therapy – How to approach Ph-like ALL Marina Konopleva, MD Anderson Cancer Center, Houston, Texas

Debate 1: Integration of immunotherapy into frontline therapy – How to tailor therapy according to MRD: when to escalate and when to de-escalate Aaron Logan, University of California, San Francisco

Debate 1: Integration of immunotherapy into frontline therapy – Panel Discussion

Session VII

Debate 2: Relapsed-Refractory disease – Immunotherapy in ALL Elias Jabbour, MD Anderson Cancer Center, Houston, Texas

Debate 2: Relapsed-Refractory disease – CAR T-cells in ALL Bijal Shah, Moffitt Cancer Center, Tampa, Florida

Debate 2: Relapsed-Refractory disease – Discussion

Debate 2: Relapsed-Refractory disease – BCL2 inhibitors in ALL Marlise Luskin, Dana-Farber Cancer Institute, Boston, Massachusetts

Debate 2: Relapsed-Refractory disease – How to optimize pediatric regimens and the use of asparaginase Wendy Stock, The University of Chicago

Debate 2: Relapsed-Refractory disease – Panel Discussion

Session VIII

Novel agents and pathways in T-ALL and ETP-ALL – Nitin Jain, MD Anderson Cancer Center, Houston, Texas

Novel CAR T approaches – Regina Myers, Childrens Hospital of Philadelphia

Older adults with ALL – Shira N Dinner, Northwestern Medicine, Feinberg School of Medicine, Chicago, IL

Future of ALL therapies – Hagop Kantarjian, MD Anderson Cancer Center, Houston, Texas

Panel Discussion

Estancia Hotel, La Jolla, California